VISCERAL ADIPOSITY
September 12, 2021ADIPOCYTE DIFFERENTIATION
September 12, 2021- SGLT inhibitors in management of diabetes
- Structural selectivity of human SGLT inhibitors
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized …
- SGLT inhibitors as antidiabetic agents: a comprehensive review
- International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors
- SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
- SGLT inhibitors for type 1 diabetes: proceed with extreme caution
- SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
- Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol
- SGLT inhibitors for type 1 diabetes: an obvious choice or too good to be true?
- The anti-inflammatory effects of SGLT inhibitors
- Na+-Glucose Cotransporter (SGLT) inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted …
- SGLT inhibitors as new therapeutic tools in the treatment of diabetes
- natural products as lead compounds for sodium glucose cotransporter (SGLT) inhibitors
- SGLT inhibitors for people with type 1 diabetes
- SGLT inhibitors: a novel target for diabetes
- Impact of SGLT inhibitors on Multiple Organ Defects in Diabetes.
- Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta …
- Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors
- Synthesis of isotopically labelled SGLT inhibitors and their metabolites
- Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense
- A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors
- QSAR studies on triazole derivatives as SGLT inhibitors via CoMFA and CoMSIA
- Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
- The bark giving diabetes therapy some bite: the SGLT inhibitors
- Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: A systematic review and network meta …
- Synthesis of L-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
- SGLT inhibitors and euglycaemic diabetic ketoacidosis: earlier observations rediscovered
- Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis‐the STOP DKA protocol
- Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
- SGLT inhibitors for type 1 diabetes
- Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors
- The bark giving diabetes therapy some bite: the SGLT inhibitors
- SGLT inhibitors attenuate NO‐dependent vascular relaxation in mouse pulmonary artery (677.3)
- SGLT inhibitors for type 1 diabetes: a finely balanced matter?
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
- Novel SGLT inhibitors (SGL5083 and SGL5085), Acting on Both Suppressing Intestinal Glucose Absorption and Increasing Urinary Glucose Excretion, Improve …
- SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
- SGLT inhibitors Enhance Endogenous Glucose Productions (EGP) in a Preclinical Animal Model
- SAT-662 Effects of SGLT inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
- Correction: Synthesis of l-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
- Sodium-glucose co-transporter (SGLT) inhibitors: a novel class of oral anti-diabetic drugs
- Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- Sodium–glucose cotransporter–2 (SGLT-2) inhibitors and the treatment of type 2 diabetes
- Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
- … -2 inhibitors and cardiovascular protection: lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 inhibitors …
- The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action
- Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists
- The Effects of DPP-4 inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history …
- SGLT-2 inhibitors-hope or hype?-an updated review
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and …
- The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 inhibitors and Pioglitazone
- PDB29 A COST-UTILITY ANALYSIS OF SODIUM-GLUCOSE COTRANSPORTER (SGLT) 2 inhibitors IN ADDITION TO BASAL-BOLUS INSULIN IN THE …
- Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic …
- Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for cardiovascular disease prevention
- Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin
- Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
- A novel SGLT-2 score to identify HFpEF patients who may benefit from SGLT-2 inhibitors
- Recent Advances on SGLT 2 inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
- Possible sodium-glucose cotransporter-2 (SGLT-2) inhibitors for reducing effects of blood glucose and also blood pressure
- Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational …
- SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
- Update on Cardiovascular Benefits with Sodium Glucose Cotransporter-2 inhibitors (SGLT-2i). On J Cardio Res & Rep. 1 (5): 2019
- Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
- Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
- Sodium-glucose cotransporter Type 2 (SGLT-2) inhibitors and ketogenesis: The Good and the Bad
- A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 inhibitors
- Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: a meta‐analysis of randomized controlled trials
- 2232: Acute kidney injury in patients on SGLT-2 inhibitors: A propensity matched analysis
- Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- 480: COMPARISON OF TREATMENT OF KETOACIDOSIS ASSOCIATED WITH SGLT-2 inhibitors AND USUAL DKA
- Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms
- Management of type 2 diabetes mellitus with overweight: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists
- Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction?
- … Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
- The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes
- Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested …
- Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events …
- SGLT-2 inhibitors and peripheral artery disease: a statistical hoax or reality?
- Use of Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
- An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
- Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
- SGLT-2 inhibitors: a new mechanism for glycemic control
- Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
- SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
- In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
- SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 inhibitors and Keto-Diet
- SGLT‐2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects
- The kidney as a new target for antidiabetic drugs: SGLT 2 inhibitors
- Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta …
- Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment
- Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors
- The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with …
- Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience
- Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
- Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on SGLT-2 inhibitors: an ongoing concern
- 194 SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
- Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes
- SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
- GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients
- Off-label prescription of SGLT-2 inhibitors to patients with type 1 diabetes: an online survey of diabetes specialists in Italy
- The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease
- SGLT 2 inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)
- Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
- The role of SGLT-2 inhibitors in the treatment of type 2 diabetes
- SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- Noninvasive monitoring of liver fat during treatment with GLP‐1 analogues and SGLT‐2 inhibitors in a real‐world setting
- Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study.
- Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
- SGLT-2 inhibitors and GLP-1 agonists: first-line therapy for diabetes with established cardiovascular disease
- The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
- A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy …
- GLP-1 Agonists and SGLT-2 inhibitors in Type 2 Diabetes Patients
- Short-and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis
- MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 inhibitors-an Under-recognized Diagnosis
- … and biological evaluation of (2S, 3R, 4R, 5S, 6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3, 4-diols as potent and orally active SGLT dual inhibitors
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
- Does gender influence the cardiovascular benefits observed with sodium glucose co-transporter-2 (SGLT-2) inhibitors? A meta-regression analysis
- Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes
- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R …
- … agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors
- Efficacy and Safety of SGLT-2 inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
- SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management?
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence
- SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL
- How do SGLT-2 inhibitors work to prevent heart failure?
- SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
- SGLT 2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature
- Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a …
- Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 inhibitors
- 4111 Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
- SGLT-2 inhibitors in heart failure: implications for the kidneys
- SGLT-2 inhibitors and their potential in the treatment of diabetes
- Emerging role of SGLT-2 inhibitors for the treatment of obesity
- SGLT 2 inhibitors act from the extracellular surface of the cell membrane
- Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- SAFETY ISSUES WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) inhibitors
- Re: diabetic ketoacidosis in patients with type 2 diabetes on SGLT-2 inhibitors: an ongoing concern
- SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies
- SGLT‐2 inhibitors and the risk of lower‐limb amputation: is this a class effect?
- … Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) inhibitors
- SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes?
- Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials
- Structure–Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) inhibitors
- Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors: Benefits in Diabetics With Cardiovascular Disease
- Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
- SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
- A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?
- Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes
- P2519 Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 …
- Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors
- Effects of GLP-1 Receptor Agonists and SGLT-2 inhibitors in Heart Transplant Patients with Type 2 Diabetes: a Case Series
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- The beneficial hemodynamic actions of SGLT-2 inhibitors beyond the management of hyperglycemia
- Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead
- Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints
- Class effect for SGLT-2 inhibitors: a tale of 9 drugs
- Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence
- Do the SGLT-2 inhibitors offer more than hypoglycemic activity?
- Adverse effects and safety of SGLT-2 inhibitors
- New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors
- 66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of …
- Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus
- Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart …
- Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors: A Review
- Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive …
- 1233-P: Systematic Literature Review (SLR) and Network Meta-analysis (NMA) of SGLT-1/2 inhibitors vs. Metformin (MET) as Add-On to Insulin in T1DM
- 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
- Comparison in Methods Between National Institute for Health And Care Excellence (Nice) Submissions For Sodium-Glucose Co-Transporter 2 inhibitors (SGLT-2i …
- The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for …
- Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic …
- SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
- SGLT-2 inhibitors for COVID-19—A miracle waiting to happen or just another beat around the bush?
- Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
- SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
- Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
- Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
- An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
- SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis
- Association Between Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors and Lower Extremity Amputation: A Retrospective Cohort Study
- Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
- SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone?
- SGLT-2 inhibitors: a novel mechanism in targeting glycemic control in type 2 diabetes mellitus
- Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced trials
- The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio-and nephroprotection
- SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
- Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations
- Elements for Success in Managing Type 2 Diabetes With SGLT-2 inhibitors: Role of the Kidney in Glucose Homeostasis: Implications for SGLT-2 Inhibition in the …
- The role of SGLT-2 inhibitors as part of optimal medical therapy in improving cardiovascular outcomes in patients with diabetes and coronary artery disease
- Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
- SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin
- Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?
- SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus: a comprehensive and critical review of the literature
- Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis
- SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
- SGLT-2 inhibitors: their pleiotropic properties
- Diabetes Consultations™: Beyond Insulin: The Role of SGLT-2 inhibitors in Care of Patients with T1DM
- In patients with uncontrolled type 2 diabetes, are GLP-1 agonists more effective than SGLT-2 inhibitors in lowering HbA1c?
- Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
- The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
- Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS
- CHARACTERISTICS OF PATIENTS INITIATING SODIUM GLUCOSE COTRANSPORTER-2 inhibitors (SGLT-2I) COMPARED TO PATIENTS INITIATING OTHER …
- SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
- Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio …
- SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
- SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
- SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
- SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes
- Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
- Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney …
- Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic …
- Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
- Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes …
- Let’s Be More Sensitive—How SGLT-2 inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes: Comment on “Improved Beta Cell Glucose …
- Letter by Tampaki et al Regarding Article,“Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 inhibitors”
- Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized …
- Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
- Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials
- SGLT-2 inhibitors in diabetes: a focus on renoprotection
- Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational …
- The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
- Mechanisms for Cardiorenal Protection of SGLT-2 inhibitors
- Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
- SGLT-2 inhibitors in development for type 2 diabetes treatment
- SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature
- Cardiovascular effects of SGLT‐2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
- Response to letter:’Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for SGLT-2 inhibitors?’
- Efficacy in metabolic control and weight loss of combined treatment with GLP-1 receptor analogues and SGLT-2 inhibitors
- SGLT-2 inhibitors in heart failure: A new therapeutic avenue
- Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management
- SGLT-2 inhibitors to treat hyponatremia associated with SIADH: a novel indication?
- Do SGLT‐2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
- Differentiating Among the SGLT-2 inhibitors: Considering Cardiovascular and Other Safety Outcomes
- … -transporter 2 inhibitors and serum uric acid: Re: Mende CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors …
- Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors And The Risk of Fractures of The Upper or Lower Limb In Patients With Type 2 Diabetes: A Nested-Case …
- Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
- Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease
- The use of SGLT-2 inhibitors in type 2 diabetes and heart failure
- Hospitalization for Heart Failure and Death in New Users of SGLT-2 inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
- A Role for SGLT-2 inhibitors in Treating Non-diabetic Chronic Kidney Disease
- Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials
- The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation
- Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the …
- Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
- Limitations of natriuretic peptide levels in establishing SGLT-2 inhibitors for heart failure care
- Prevention of cardiac allograft vasculopathy–A new possible indication for SGLT-2 inhibitors?
- SGLT-2 inhibitors as cardioprotective agents in COVID-19
- Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 inhibitors and GLP-1 Analogs?
- SGLT-2 inhibitors Use in Renal Transplant Patients with Diabetes: A Brief Review of the Current Literature.
- Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 inhibitors versus Other Glucose Lowering Drugs-Real World Data Across …
- SGLT-2 inhibitors Beneficial Effects on Ventricular Repolarization May Be Protective against Atrial Fibrillation Occurrence
- SGLT-2 inhibitors and regenerative cell exhaustion
- Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 inhibitors.
- SGLT-2 inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
- The effect of SGLT‐2 inhibitors on mortality and heart failure in randomized trials versus observational studies
- … Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 inhibitors (SGLT …
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 …
- SGLT‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study
- SGLT-2 inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
- Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a …
- Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
- SGLT‐2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database
- Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
- Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery
- Effects of cardiovascular function of SGLT-2 inhibitos versus DPP-4 inhibitors in type 2 diabetes with coronary artery disease
- Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus-Is it empaglifozin or the class?
- SGLT-2 inhibitors in diabetic kidney disease: what lies behind their renoprotective properties?
- Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials
- Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials
- … THE DIFFERENCES EFFECTS OF GLUCAGON LIKE PEPTIDE-1 (GLP-1) ANALOGUES AND SODIUM-COTRANSPORTER 2 (SGLT-2) inhibitors ON TYPE 2 …
- Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease …
- Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: Systematic review with meta-analysis and trial …
- A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d/KLF9/VEGFA pathway
- SGLT-2 inhibitors in Heart Failure: Volume or Value?
- SGLT-2 inhibitors users profile recruited through a pharmacy-based intensive monitoring study: analysis of the pharmacotherapeutic profile, drug-drug interactions …
- The role of SGLT-2 inhibitors in managing type 2 diabetes.
- Use of SGLT-2 inhibitors in Patients With Type 1 Diabetes Mellitus
- In Reply to ‘Do SGLT-2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
- Postoperative euglycemic diabetic ketoacidosis and encephalopathy related to SGLT-2 inhibitors: a case report and discussion of diabetes treatment and “sweet pee …
- Trends in SGLT-2 inhibitors Usage in Heart Failure Patients With Type 2 Diabetes Mellitus, in a South-East Queensland Hospital
- SGLT-2 inhibitors for people with type 2 diabetes–Authors’ reply
- … and patient-centred outcome measures in randomized controlled trials conducted for diabetes pharmacotherapy: SGLT-2 receptor inhibitors as an example
- Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril–valsartan: does money matter?
- SGLT-2 inhibitors: are they a promising treatment option in T2DM patients with NAFLD?
- Do SGLT-2 inhibitors reduce albuminuria in people with diabetes?
- Renal Effects of SGLT‐2 inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks
- Ketogenic Diets, Ketoacidosis and SGLT-2 inhibitors-Part 2..
- Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction
- MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic …
- … Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 inhibitors in Two Large …
- SGLT-2 inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
- Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
- … Reporting and Data System Category 3 (Equivocal) Lesions Identified Infection and Inflammation of the Genitourinary Tract Re: SGLT-2 inhibitors and the Risk of …
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
- Falls and SGLT-2 inhibitors in geriatric patients—A case report
- The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes
- Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
- A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 inhibitors by HPLC in Its API and Dosage Form
- Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 inhibitors
- Euglycemic Diabetic Ketoacidosis, SGLT-2 inhibitors and COVID-19; The Murphy Law of COVID-19
- Development of Efficient Routes to Access C-Glycosides as SGLT-2 inhibitors for the Treatment of Type 2 Diabetes
- Current Utilization Trends of SGLT-2 inhibitors in Type 2 Diabetics With Heart Failure
- SGLT-2 inhibitors for people with type 2 diabetes
- The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
- SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
- SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes
- P2482 Sex-based differences in cardioprotective role of SGLT-2 inhibitors in patients with type 2 diabetes mellitus
- Correlations Between SGLT-2 inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs
- Expect the Unexpected: SGLT-2 inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure
- Analysis of Adverse Drug Reactions Induced by SGLT-2 inhibitors
- SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
- SGLT-2 inhibitors DEMONSTRATE CONSISTENT REDUCTION IN CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATIONS AN UP-TO …
- Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus
- The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
- Glycosuria with SGLT-2 inhibitors–a new treatment approach for type 2 diabetes mellitus
- SGLT-2 inhibitors and circulating progenitor cells in diabetes
- Improving Glucose Control in Type II Diabetes with SGLT-2 inhibitors and GLP-1 Agonists
- Do SGLT-2 inhibitors improve cardiovascular outcomes in patients with type 2 diabetes?
- SGLT-2 inhibitors for people with type 2 diabetes
- Kidney Outcomes With SGLT-2 inhibitors
- SGLT-2 inhibitors and nephroprotection: a systematic review and meta-analysis
- SGLT-2 inhibitors-are they to stay?
- SGLT-2 inhibitors as adjunct therapy in type 1 diabetes: reason for hope and caution
- The method of reporting hypoglycemia in randomized control trials (RCTs): a systematic review on RCTs conducted for SGLT-2 inhibitors
- SGLT-2 inhibitors: The glucosuric antidiabetics
- SYSTEMATIC REVIEW OF COST-EFFECTIVENESS OF SGLT-2 inhibitors IN TYPE 2 DIABETES MELLITUS
- SGLT-2-inhibitors in Heart Failure
- SGLT 2 inhibitors: a new therapeutic target and its role in current clinical practice
- Renoprotective effect of SGLT-2 inhibitors vs ACE inhibitors in type 2 diabetes (presentation)
- Renoprotective effect of SGLT-2 inhibitors vs ACE inhibitors in type 2 diabetes
- FO042 EFFECT OF SGLT-2 inhibitors ON AMBULATORY BLOOD PRESSURE: DOSE-RESPONSE META-ANALYSIS AND COMPARATIVE EVALUATION WITH …
- Need of the hour: pharmacovigilance study of SGLT-2 inhibitors
- PDB13-SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 inhibitors AND METFORMIN AS ADD-ON TO INSULIN FOR THE …
- Diabetes Management and Cardiovascular Risk: Are SGLT-2 inhibitors the Safest?
- The effect of SGLT-2 inhibitors on albuminuria and proteinuria in Diabetes Mellitus: a systematic review and meta–analysis of randomized controlled trials
- Falls and SGLT-2 inhibitors in geriatric patients—A
- SGLT 2 inhibitors improve cardiorenal outcomes in DM2–get rid of the sugar
- A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS …
- MON-LB029 The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients …
- KETOACIDOSIS GENERATED BY TREATMENT WITH SGLT-2 inhibitors–A CASE REPORT
- Victoza®(liraglutide) provides greater glycaemic control than SGLT-2 inhibitors
- A Meta-Analysis of the Effects of SGLT-2 inhibitors on Serum Electrolytes
- Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials
- REAL WORLD SAFETY AND EFFICACY OF SGLT-2 inhibitors IN ELDERLY TYPE 2 DIABETIC PATIENTS
- The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on Mortality Risk in Elderly Patients with Type 2 Diabetes
- Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters
- Prescribing patterns of SGLT-2 inhibitors and GLP-1 agonist in patients with both DM and ASCVD
- SGLT-2 inhibitors
- TREATMENT WITH SGLT-2 inhibitors IN PATIENTS WITH DIABETES MELLITUS AND ESSENTIAL HYPERTENSION–DYNAMIC OF BLOOD PRESSURE VISIT-TO …
- Use of SGLT-2 inhibitors in Patients with Chronic Kidney Disease.
- Effect of SGLT-2 inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta …
- Effects of SGLT-2 inhibitors and Visceral Fat on Glucose Metabolism
- SGLT-2 inhibitors and amputation: A real or an overestimated risk?
- SGLT-2 inhibitors: a new therapy for diabetes
- SGLT-2 inhibitors as adjunctive therapy in type 1 diabetes: Short experience from a center
- SGLT-2 inhibitors: An Evidence-Based Perspective
- Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists
- A Multivariate Safety and Efficacy Analysis of Prescribing Information for Next Generation SGLT-2 inhibitors in Type 2 Diabetes Treatment
- SGLT-2 inhibitors in type 2 diabetes-protecting the kidney (and heart) beyond glucose control
- WHAT PHYSICIANS NEED TO KNOW ABOUT SGLT-2 inhibitors
- Cerebrovascular Complications of Diabetes: SGLT-2 inhibitors as a Promising Future Therapeutics.
- SGLT-2 inhibitors–aT The LimiTS
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
- SGLT inhibitor adjunct therapy in type 1 diabetes
- Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
- Sodium-glucose co-transporter (SGLT) inhibitor restores lost axonal varicosities of the myenteric plexus in a mouse model of high-fat diet-induced obesity
- Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases
- Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
- Pharmacological investigations on efficacy of Phlorizin a sodium-glucose co-transporter (SGLT) inhibitor in mouse model of intracerebroventricular streptozotocin …
- Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
- Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT inhibitor Phlorizin
- The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE−/− mice
- 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized …
- DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
- Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter …
- Glycemic effects of SGLT-2 inhibitor Canagliflozin in type 1 diabetes patients using the dexcom G4 platinum CGM
- Consensus Report on Diabetic Ketoacidosis and Adjunctive SGLT inhibitor Therapy in Type 1 Diabetes
- The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with …
- Effects of the SGLT-2 inhibitor empagliflozin on renal tissue oxygenation in non-diabetic subjects: a randomized, double-blind, placebo-controlled study …
- Novel SGLT inhibitor (SGL5094) Improves Postprandial Hyperglycemia Through the Suppression of SGLT1-Mediated Glucose Transport Across the Small Intestine.
- Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model
- … , tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese …
- Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
- Efficient Synthesis of Empagliflozin, an inhibitor of SGLT-2, Utilizing an AlCl3-Promoted Silane Reduction of a β-Glycopyranoside
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats …
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
- Empagliflozin, SGLT 2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of Klotho expression
- Renoprotective effects of combined SGLT 2 and ACE inhibitor therapy in diabetic D ahl S rats
- SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM
- Effects of the sodium‐glucose cotransporter 2 (SGLT 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
- Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic …
- Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
- Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT) 1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 …
- … and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
- Off-target effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitor in cardiovascular disease
- A validated LC‐MS/MS method for the determination of canagliflozin, a sodium–glucose co‐transporter 2 (SGLT‐2) inhibitor, in a lower volume of rat plasma …
- The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical …
- A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK-and HNF1A-MODY than in type 2 diabetes mellitus
- Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
- The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
- Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin
- Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2
- Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis
- A quantitative LC–MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in …
- Effect of a selective SGLT 2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
- Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation
- SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals …
- Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
- Liraglutide and dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational …
- SGLT-2 inhibitor intervention in diabetes mellitus patients can reduce the incidence of renal injury and adverse events
- SGLT‐2 inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk
- Profile of Ipragliflozin, an Oral SGLT-2 inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
- Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report
- Synthesis of SGLT-2 inhibitor Empagliflozin
- Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
- 442: Diagnosis and Management of SGLT-2 inhibitor-Induced Euglycemic DKA After Cardiac Surgery
- Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
- A practical stereoselective synthesis and novel cocrystallizations of an amphiphatic SGLT-2 inhibitor
- The SGLT-2 inhibitor empagliflozin preserves beta cell mass and restores glucose homeostasis in the male diabetic ZDF rat
- US Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Therapy
- Ertugliflozin: a new option in the SGLT-2 inhibitor market for the treatment of type 2 diabetes mellitus
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
- Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
- Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor
- Abstract# 1040609: SGLT-2 inhibitor Prescribing Patterns at Tertiary Care Diabetes Center for Individuals with Diabetes and Heart Failure
- … for cost-savings in the elderly Ontarian population with type 2 diabetes due to reduction in mild hypoglycemia events for SGLT-2 inhibitor versus sulfonylurea (SU) …
- Tubuloglomerular feedback in renal glucosuria: mimicking long-term SGLT-2 inhibitor therapy
- … -1 RECEPTOR AGONIST AND SGLT-2 inhibitor COMBINATION ON BLOOD PRESSURE LEVELS COMPARED TO SGLT-2 inhibitor ALONE: A SYSTEMATIC …
- The SGLT-2 inhibitor dapagliflozin reduces cell death and apoptosis in cardiomyocytes exposed to trastuzumab and doxorubicin through NLRP3-mediated pathways.
- Euglycemic diabetic ketoacidosis precipitated by SGLT-2 inhibitor use, pericarditis, and fasting: a case report
- Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter (SGLT) 2 inhibitor after coronary artery bypass grafting
- P722 Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
- P2295 SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation
- … stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor
- Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects
- Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport inhibitor (SGLT-2i), a Case Report
- Sodium Glucose Cotransporter-2 (SGLT-2) inhibitor Related Diabetic Ketoacidosis
- About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes
- Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitor drugs: Assessment of safety in Fasting Diabetics
- Abstract# 998903: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
- Abstract# 1000873: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
- A promising combination for future treatment of type 2 diabetes: Coadministration of empagliflozin (SGLT-2 inhibitor) with linagliptin (DPP-4 inhibitor)
- Evaluation of glycemic control by metformin+ glitazone+ DPP-4 inhibitor+ SGLT-2 inhibitor combination in patients with type 2 diabetes quitting basal/bolus …
- US Prevalence Estimates of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Initiation
- Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
- Renal outcomes and all-cause death associated with SGLT-2 inhibitor versus other glucose-lowering drugs (CVD-REAL 3 Korea).
- Individualizing treatment with SGLT-2 inhibitor therapy in type 2 diabetes mellitus
- Abstract P233: Sodium Glucose Transporter Type-2 (SGLT-2) inhibitor, Empagliflozin, Improves Cardiovascular Outcomes in Female Diabetic db/db Mice Independent …
- Rare Infection Linked With SGLT-2 inhibitor Use
- Unmasking Type–1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 inhibitor Use: A Case Report
- A case series of sodium glucose co-transporter-2 inhibitor (SGLT-2i) related diabetic ketoacidosis and literature review of the possible pathophysiology
- Effect of SGLT-2 inhibitor Therapy on Cardiovascular Health in Diabetes Mellitus Patients
- Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
- SUN-180 Successful Use of SGLT-2 inhibitor Dapagliflozin in Three Patients with Renal Transplant and Diabetes: A Fruit for Thoughts
- SGLT-2 inhibitor-INDUCED DKA: UNMASKING OF LATENT AUTOIMMUNE DIABETES IN ADULTS. CAN WE DO BETTER?
- Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
- A Case of Euglycemic DKA With SGLT 2 inhibitor Use-A Diagnostic and Therapeutic Dilemma
- Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication
- 5.1 EFFECTS OF THE SGLT-2 inhibitor EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 …
- … agonist; empagliflozin (Jardiance®, Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia®, Merck), a DPP-4 inhibitor. However, we do …
- BITTER-SWEET DKA: A CASE OF SGLT-2 inhibitor INDUCED EUGLYCEMIC DKA IN A TYPE-1 DIABETIC PATIENT
- SGLT 2 inhibitor induced euglycemic ketoacidosis
- BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on …
- The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-glucose co-transporter 2 (SGLT-2)
- Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 inhibitor Use and Recent Sleeve Gastrectomy
- First‐dose effect of the SGLT 2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats
- Fournier’s gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: A double trouble
- Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: a case report
- Acute interstitial nephritis related to SGLT-2 inhibitor
- … mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in …
- Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
- Euglycemic Diabetic Ketoacidosis in a Patient on a SGLT-2 inhibitor Presenting with Acute Pancreatitis
- Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) inhibitor
- Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes
- Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes: a retrospective study
- Euglycemic Diabetic Ketoacidosis With SGLT-2 inhibitor
- Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between …
- Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case …
- SHOULD CARDIOLOGIST PRESCRIBE AN SGLT-2 inhibitor?
- Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes
- Acute Renal Failure With Cocaine and SGLT-2 inhibitor
- GLP-1RA as Add-on Therapy to SGLT-2 inhibitor
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
- Effect of SGLT-2 inhibitor on Bone Turnover in Overweight and Obese Patients with Type 2 Diabetes
- Choosing an SGLT-2 inhibitor for a patient with type 2 diabetes: Which agent (if any) is best
- Effect of tofogliflozin, a SGLT-2 inhibitor, on diabetic ocular complications in SDT rats
- Identification on Anti-Atherosclerotic Mechanism of SGLT-2 inhibitor in Diabetic Rabbit Model
- Upregulation of Toll-Like Receptors That Underlies Diabetes-Induced Exacerbation of Cardiorenal Syndrome is Attenuated by Canagliflozin, an SGLT-2 inhibitor
- Effects of Combination of SGLT-2 inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria: A Case Series
- Hyperglycemic Diabetic ketoacidosis precipitated by an SGLT-2 inhibitor in a non-insulin dependant type 2 diabetic
- Effects of SGLT-2 inhibitor on mitochondrial function in renal proximal tubular cell
- SGLT-2 inhibitor: A Unique Antidiabetic in Type 2 Diabetes Mellitus
- Sodium dependent glucose transporter (SGLT) 1/2-elucidating inhibitor SAR and selectivity using homology modelling and 3D QSAR studies.
- Euglycemic DKA after initiating an SGLT-2 inhibitor and the P90X diet
- Effect of dual sodium-glucose cotransporter (SGLT)-1/2 inhibitor sotagliflozin on glycemic and nonglycemic outcomes and on hypoglycemia in type 1 diabetes. A meta …
- Farxiga (Dapagliflozin), an Oral SGLT-2 inhibitor, a New FDA-Approved Treatment Option for Type 2 Diabetes
- Hydrogen-bonded structures and interaction energies in two forms of the SGLT-2 inhibitor sotagliflozin
- Dapagliflozin (forxiga®): SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes
- Ketoacidosis with SGLT-2 inhibitor and Ketogenic Diet: A Case Study
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- SGLT2 inhibitors may predispose to ketoacidosis
- An update on the safety of SGLT2 inhibitors
- SGLT2 inhibitors: are they safe?
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- Possible adverse effects of SGLT2 inhibitors on bone
- A review on the relationship between SGLT2 inhibitors and cancer
- SGLT2 inhibitors and the diabetic kidney
- Risks associated with SGLT2 inhibitors: an overview
- SGLT2 inhibitors
- An update on SGLT2 inhibitors for the treatment of diabetes mellitus
- SGLT2 inhibitors and mechanisms of hypertension
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- Development of SGLT1 and SGLT2 inhibitors
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- Effects of SGLT2 inhibitors on cardiovascular outcomes
- Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
- SGLT2 inhibitors: their potential reduction in blood pressure
- SGLT2 inhibitors as a therapeutic option for diabetic nephropathy
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
- SGLT2 inhibitors in the treatment of type 2 diabetes
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- SGLT2 inhibitors: the latest “new kids on the block”!
- Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
- SGLT2 inhibitors: molecular design and potential differences in effect
- Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
- SGLT2 inhibitors: benefit/risk balance
- Acute kidney injury from SGLT2 inhibitors: potential mechanisms
- Promise of SGLT2 inhibitors in heart failure: diabetes and beyond
- Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
- Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors
- Metabolism of the failing heart and the impact of SGLT2 inhibitors
- Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
- Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?
- SGLT2 inhibitors in the management of type 2 diabetes
- Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
- Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?
- Uric acid and the cardio‐renal effects of SGLT2 inhibitors
- SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
- The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
- SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
- Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
- SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management
- Synthetic strategies toward SGLT2 inhibitors
- SGLT2 inhibitors and the kidney: effects and mechanisms
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
- Practical approach to initiating SGLT2 inhibitors in type 2 diabetes
- SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus
- SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
- The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- Are SGLT2 inhibitors ready for prime time for CKD?
- The renal effects of SGLT2 inhibitors and a mini-review of the literature
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
- Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives
- Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
- SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
- SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice
- SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
- The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58
- Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
- SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
- Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
- SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
- Does lower limb amputation concern all SGLT2 inhibitors?
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- Adverse effects of SGLT2 inhibitors on bone health
- Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors
- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
- Acute kidney injury and adverse renal events in patients receiving SGLT2–inhibitors: a systematic review and meta-analysis
- SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
- SGLT2 inhibitors: nephroprotective efficacy and side effects
- SGLT2 inhibitors: β blockers for the kidney?
- Adoption of new glucose-lowering medications in the US—the case of SGLT2 inhibitors: nationwide cohort study
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
- Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind …
- SGLT2 inhibitors in T2D and associated comorbidities—differentiating within the class
- Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
- SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus
- SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney …
- The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
- SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
- Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review
- Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using …
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
- SGLT2 inhibitors and urinary tract infections
- Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
- Safety of SGLT2 inhibitors in patients with diabetes mellitus
- Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale …
- SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review
- Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care
- Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis
- Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
- SGLT2 inhibitors and diabetic ketoacidosis—a growing concern
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
- The role of kidney in glucose homeostasis–SGLT2 inhibitors, a new approach in diabetes treatment
- SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
- SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
- The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
- Risk of amputations associated with SGLT2 inhibitors compared to DPP‐4 inhibitors: a propensity‐matched cohort study
- SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials
- SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
- The role of the kidney and SGLT2 inhibitors in type 2 diabetes
- Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
- Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
- Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
- SGLT2 inhibitors: practical considerations and recommendations for cardiologists
- Discovery of non-glucoside SGLT2 inhibitors
- Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm
- Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and …
- SGLT2 inhibitors‘ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
- Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
- Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
- Clinical implication of SGLT2 inhibitors in type 2 diabetes
- Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus
- ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
- SGLT2–inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2–inhibitors in clinical practice
- SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
- Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction
- SGLT2 inhibitors for diabetes: turning symptoms into therapy.
- Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes
- Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry
- The expanding résumé of SGLT2 inhibitors
- Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
- Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition
- Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes
- Update on SGLT2 inhibitors—new data released at the American Diabetes Association
- Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: implications for clinical practice
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
- Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
- Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
- Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1, 3, 4-thiadiazolylmethylphenyl glucoside congeners
- SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes
- SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
- Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia
- Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials
- The role of SGLT2 inhibitors in managing type 2 diabetes
- SGLT2 inhibitors and cancer: why further evidence is required
- Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
- Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
- Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors
- Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media
- SGLT2 inhibitors and risk of genitourinary infections
- The effect of SGLT2 inhibitors on cardiovascular events and renal function
- SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
- The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
- Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
- Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus
- SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
- Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
- Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk
- Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
- Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an …
- How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology
- A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy …
- … -glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review
- SGLT2 inhibitors in the real world: too good to be true?
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide
- Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta‐analysis of randomized controlled trials
- SGLT2 inhibitors and protection against pancreatic beta cell failure
- Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes
- Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors
- A fluorescent glucose transport assay for screening SGLT2 inhibitors in endogenous SGLT2-expressing HK-2 cells
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
- SGLT2 inhibitors and heart failure—clinical implications
- Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs
- The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
- Use of SGLT2 inhibitors during Ramadan: a survey of physicians’ views and practical guidance
- SGLT2 inhibitors in Type 1 diabetes: is this the future?
- A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
- An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
- Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta‐analysis
- SGLT2 inhibitors race to enter type-2 diabetes market
- Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543
- SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?
- Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient
- How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European …
- Facile synthesis of 1, 2, 3-triazole analogs of SGLT2 inhibitors by ‘click chemistry’
- Type 2 diabetes, SGLT2 inhibitors, and glucose secretion
- The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
- The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
- Potential place of SGLT2 inhibitors in treatment paradigms for type 2 diabetes mellitus
- Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
- Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus
- Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
- SGLT2 inhibitors—Sweet Success for Diabetic Kidney Disease?
- Recent developments of C-aryl glucoside SGLT2 inhibitors
- SGLT2 inhibitors in development
- Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative …
- … of SGLT2 and SGLT1: a quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
- Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes
- SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
- Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
- SGLT2 inhibitors and the risk of diabetic ketoacidosis
- Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 inhibitors
- … involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in …
- Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure
- Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
- Comparative risk of genital infections associated with SGLT2 inhibitors: a real-world retrospective cohort study
- SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites
- How does CREDENCE inform best use of SGLT2 inhibitors in CKD?
- Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents
- What next after metformin? Thinking beyond glycaemia: are SGLT2 inhibitors the answer?
- Design, synthesis and in vivo hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents
- Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview
- Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis
- The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
- Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs
- Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
- Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists
- SGLT2 inhibitors might halt progression of diabetic nephropathy
- Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Further insights into SGLT2 inhibitors
- Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases
- A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
- 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
- Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
- SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
- Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
- The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
- Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
- Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control
- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- Design and synthesis of fluorescent SGLT2 inhibitors
- CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
- Drug–drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes …
- Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans
- Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Treatment of Type 2 Diabetes
- C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents
- How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a population …
- Use of SGLT2 inhibitors in diabetic renal transplant recipients: a mixed method exploratory exercise
- Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 inhibitors for type 2 diabetes
- When insulin therapy fails: the impact of SGLT2 inhibitors in patients with type 2 diabetes
- SGLT2 inhibitors enter crowded diabetes space
- Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
- Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG
- Preventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors
- Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis
- SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule?
- Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of type 2 diabetes
- Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Synthesis and Biological Evaluation
- Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
- 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice
- Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- Discovery of Novel N-β-d-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Management of Hyperglycemia in …
- Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent
- Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
- Efficacy and safety of SGLT2 inhibitors in reducing glycated hemoglobin and weight in emirati patients with type 2 diabetes
- Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2–inhibitors trigger downstream mechanisms that may exert adverse effects upon bone
- Remarkable improvement of glucose variability by Sodium–glucose cotransporter 2 (SGLT2) inhibitors using continuous glucose monitoring (CGM)
- SGLT2 inhibitors-moving on with the evidence.
- Chances and risks of SGLT2 inhibitors
- Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
- … to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors
- Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
- Atom-based 3D QSAR studies on novel N-β-d-xylosylindole derivatives as SGLT2 inhibitors
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review
- Type 2 sodium-glucose cotransporter (SGLT2) inhibitors: from familial renal glucosuria to the treatment of type 2 diabetes mellitus
- Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new’French paradox’.
- Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus
- Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2
- Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the Yin and Yang of glucagon?
- SGLT2 inhibitors and the changing landscape for treatment of diabetes
- Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors
- Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors
- Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database
- Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, pramlintide, colesevelam, SGLT2 inhibitors, tagatose, succinobucol
- Will SGLT2 inhibitors prove to be a ‘multiple’gamechanger?
- Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs
- When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
- Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors
- Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors
- Response to comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018; 41: 6–10
- Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
- Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug …
- Essentials of SGLT2 inhibitors in Diabetes
- Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors
- Possible new inflammatory side-effect of SGLT2–inhibitors: fixed drug eruption
- A rose by any other name: ketoacidosis due to SGLT2 inhibitors reveals latent autoimmune diabetes
- Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
- Palladium‐Catalyzed Arylation of Carbasugars Enables the Discovery of Potent and Selective SGLT2 inhibitors
- Renal and cardiac implications of sodium glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
- Thiadiazole‐based thioglycosides as sodium‐glucose co‐transporter 2 (SGLT2) inhibitors
- O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
- C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization
- Unsweetening the heart: possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects
- ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 versus DPP4 inhibitors for type 2 diabetes
- … and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of …
- Drugs for diabetes: part 8 SGLT2 inhibitors
- SGLT2 inhibitors in diabetes mellitus treatment
- 5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study
- A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
- Bolstering your armamentarium with SGLT2 inhibitors
- Sweet success? SGLT2 inhibitors and diabetes
- Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) inhibitors
- Potential role of SGLT2 inhibitors in the management of type 1 diabetes
- SGLT2 inhibitors suppress NLRP3 inflammasome activity via changes in ketones and insulin in type 2 diabetes and cardiovascular diseases
- C-Aryl 5a-carba-β-D-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors
- Sodium-glucose linked transporter 2 (SGLT2) inhibitors—fighting diabetes from a new perspective
- Repurposing SGLT2 inhibitors
- Sodium glucose transporter 2 (SGLT2) inhibitors: Current status in clinical practice.
- Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors
- Development of sodium glucose co-transporter 2 (SGLT2) inhibitors with novel structure by molecular docking and dynamics simulation
- Combined HQSAR, topomer CoMFA, homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors
- How low do we fall to lower hemoglobin A1c? SGLT2 inhibitors: Effective drugs or expensive toxins!
- SGLT2 inhibitors for type 2 diabetes mellitus treatment
- … now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement …
- Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition
- Predicting the biological activities of triazole derivatives as SGLT2 inhibitors using multilayer perceptron neural network, support vector machine, and projection …
- A Systematic Review of Analytical Profiles of SGLT2 inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus
- Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin
- Heart Failure Prevention with SGLT2 inhibitors
- SGLT2 inhibitors: a new generation of antidiabetic drugs
- Effects of SGLT2 inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
- Synthetic and biological studies of carbasugar SGLT2 inhibitors
- SGLT2 inhibitors Therapy in Type 2 Diabetes Mellitus
- Acidosis without marked hyperglycemia: Euglycemic diabetic ketoacidosis associated with SGLT2–inhibitors
- Development of a method to study the activity and selectivity of SGLT2 inhibitors
- A new and improved process for C-aryl glucoside SGLT2 inhibitors
- C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type …
- Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
- Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases
- Correction to “Synthetic Strategies toward SGLT2 inhibitors”
- … with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 …
- SUN-177 house of Carbs: the path to euglycemic Dka in patients with diabetes on SGLT2 inhibitors
- β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 inhibitors
- Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
- Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and …
- SGLT2 inhibitors: A Review of Canagliflozin
- SGLT2 inhibitors: rationale and perspectives of use in heart failure
- P2484 SGLT2 inhibitors in diabetes with CKD
- Comment on Suissa. Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
- SGLT2 inhibitors: not just another glucose-lowering agent
- SGLT2 inhibitors: Far too many cautions and alerts and limited efficacy
- An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus
- Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside inhibitors of SGLT2
- Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors
- Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus
- SGLT2–inhibitors in type-2 diabetes: The remaining questions!
- gem‐Dimethyl‐bearing C‐Glucosides as Sodium‐glucose Co‐transporter 2 (SGLT2) inhibitors
- 247-OR: real-world effectiveness of SGLT2 inhibitors vs. GLP-1 receptor agonists in patients with and without cardiovascular disease
- Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
- Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Stroke―Reply―
- SGLT2 inhibitors and ketoacidosis: pathophysiology and management
- 156-OR: Risk-Benefit of SGLT2 inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
- SGLT2 inhibitors and euglycemic ketoacidosis
- Should we be combining GLP-1 receptor agonists and SGLT2 inhibitors in treating diabetes?
- SGLT2 inhibitors: cardiovascular benefits beyond glycemic control
- Molecular modeling studies of thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
- SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus
- Cardiovascular benefit of SGLT2 inhibitors in the therapeutics of diabetes mellitus: A close look beyond the horizon
- The role of SGLT2 inhibitors in type 2 diabetes
- Recognizing low endogenous insulin production as a precipitating factor of DKA in type-2 diabetic patients taking SGLT2 inhibitors: a case report
- Utility of SGLT2 inhibitors in patients with chronic heart failure with diabetes mellitus
- … Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 inhibitors to the Improvement …
- Effects of SGLT2 inhibitors on Insulin Secretion and Insulin Resistance—Results from a Cross-Sectional Study
- Comparative Cardiovascular Effectiveness of SGLT2 inhibitors vs. Liraglutide in Routine Care
- Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
- Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
- P317 A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study …
- SGLT2 inhibitors reduce major adverse cardiovascular events in type 2 diabetic patients: a meta-analysis of randomized controlled trials
- Cardiac Energy Metabolism and the Role of SGLT2 inhibitors in Heart Failure
- SGLT2 inhibitors
- SGLT2 inhibitors compared with sitagliptin as add-on therapy to metformin in type 2 diabetes: a systematic review and meta-analysis
- Erratum. SGLT2 inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018; 41: 1543 …
- DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 inhibitors: A REAL WORLD APPROACH
- Sodium glucose co-transporter 2 (SGLT2) inhibitors in type 2 diabetes: a literature review of approved products
- 1227-P: GlycoMark 1, 5-Anhydrocluitol values in patients taking SGLT2 inhibitors
- Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors
- … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
- Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2
- Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
- Therapeutic Potential of SGLT2 inhibitors in Treating Type 2 Diabetes Mellitus
- Fournier’s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: Our experience
- SGLT2 inhibitors suppress alpha-adrenergic tone and morning elevation of plasma glucose levels
- Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors from Sophora flavescens.
- Complementarity between randomised controlled trials and observational registries: the example of cardiovascular prevention with SGLT2 inhibitors
- Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics …
- Sodium Glucose Co-transporter Type 2 (SGLT2) inhibitors in CKD
- Euglycemic ketoacidosis: a complication of SGLT2 inhibitors
- SGLT2 inhibitors
- 2343-PUB: reduction of HbA1c after SGLT2 inhibitors correlate with change in plasma osmolarity but not with elevation of hematocrit in Japanese patients with type 2 …
- 1, 2, 4-Triazinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
- NON-CARDIAL EFFECTS OF SGLT2 inhibitors (REVIEW)
- The Elevation of Hematocrit after Administration of SGLT2 inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes
- A Significance of Sodium-Glucose Cotransporter 1 (SGLT1) Inhibition by SGLT2 inhibitors
- SGLT2 inhibitors
- The Benefits of SGLT2 inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
- Spiroketal Phthalane C-Glycosides: Synthesis of Papulacandins and SGLT2 inhibitors
- SUN-181 case report: rare complication of SGLT2 inhibitors can occur only 10 days after starting the medication
- SGLT2 inhibitors cost effective versus sulfonylureas in T2DM
- Comment on” comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in …
- P272 Additional use of SGLT2 inhibitors in the treatment of acute decompensated heart failure may prevent acute kidney injury
- FP499 PHARMACODYNAMIC REASON WHY THE DOSE OF SGLT2 inhibitors SHOULD NOT BE REDUCED IN PATIENTS WITH GFR LESS THAN 45 ML/MIN
- Os 32-05 Effects of SGLT2 inhibitors on circadian rhythm of blood pressure in rats
- How to use SGLT2 inhibitors safely
- … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
- Annals On Call-SGLT2 inhibitors: The Good, the Bad, and the Ugly
- 2275-PUB: Relationship between the Effect of SGLT2 inhibitors and Dietary Intake in Japanese Patients with Type 2 Diabetes
- Exploration of novel C-glucoside formation and application for SGLT2 inhibitors-Discovery of canagliflozin as a SGL T2 inhibitor
- What Are The Benefits In The Association Of SGLT2 inhibitors And Other Drugs?
- Leaving the Glucocentric View: Can SGLT2 inhibitors Halt CVD in Patients With Type 2 Diabetes?
- Mechanisms and efficacy of SGLT2 inhibitors
- Efficiency and safety of SGLT2 inhibitors
- Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018
- Using SGLT2 inhibitors in Special Populations
- The SGLT2 inhibitors-a review: original
- A Review on Efficacy and Safety of SGLT2 inhibitors as Add-on Therapy with Metformin
- RENOPROTECTIVE EFFECTS OF SGLT2 inhibitors
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke
- Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men
- SGLT2 inhibitors for Treating Diabetes
- GLYCEMIC OUTCOMES OF SGLT2 inhibitors IN OVERWEIGHT OR OBESE TYPE 2 DIABETES PATIENTS
- House of Carbs: the path to euglycemic DKA in patients with Diabetes on SGLT2 inhibitors
- In Silico Design Of Compounds As SGLT2 inhibitors
- The combination of GLP-1 analogs and SGLT2 inhibitors: new perspectives?
- Combination therapy with once weekly GLP 1 receptor agonist dulaglutide and SGLT2 inhibitors in Asian Indians with type 2 diabetes
- SGLT2–inhibitors and cardiovascular outcomes: inferences for clinical practice
- The Role of SGLT2 inhibitors in Clinical Practice
- SGLT2 inhibitors in Diabetes mellitus
- A NOVEL ROLE OF SGLT2 inhibitors TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND …
- Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of Ramadan in Muslim patients with type 2 diabetes
- CLINCIAL EXPERIENCE WITH THE USE OF SODIUM GLUCOSE TRANSPORTERS SGLT2 inhibitors IN AN ENDOCRIONOLOGY OUTPATIENT CLINIC IN …
- THE ROLE OF SGLT2 inhibitors IN TYPE 2 DIABETES
- SAT-298 EFFECT OF SGLT2 inhibitors ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS …
- Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 inhibitors in Type 2 Diabetes Management: Key Evidence and …
- SGLT2 inhibitors: Now The Bad News
- The Use of SGLT2 inhibitors in Elderly Patients with Type 2 Diabetes Mellitus
- SGLT2 inhibitors for type 2 diabetes: Clinical considerations
- … Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 inhibitors, GLP-1 Receptor Agonists, and SGLT2 inhibitors
- Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
- Erratum to: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: A systematic review
- Erratum to: sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
- TO STUDY THE SAFETY AND EFFICACY OF SGLT2 inhibitors AND OTHER ORAL HYPOGLYCAEMIC AGENTS WITH INSULIN IN UNCONTROLLED TYPE …
- MON-170 OUTCOMES OF SGLT2 inhibitors USE IN DIABETIC RENAL TRANSPLANT PATIENTS-SINGLE CENTER EXPERIENCE
- Cardiovascular safety of SGLT2 inhibitors
- A New Weapon in the Fight Against Diabetes: SGLT2 inhibitors
- SGLT2 inhibitors in T2D and associated comorbidities-differentiating within the class: correspondence
- … of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) inhibitors: A …
- COMPARISON OF EFFECTIVENESS OF SGLT2 inhibitors IN THE INDIAN MULTI ETHINIC TYPE 2 DIABETES PATIENTS-REAL WORLD EXPERIENCE
- SAT-LB013 The Effect of Select GLP1 Agonists and SGLT2 inhibitors on the Unfolded Protein Response in Primary Human Coronary Artery Endothelial Cells
- Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
- Erratum to: practical approach to initiating SGLT2 inhibitors in type 2 diabetes
- Synthetic Studies towards Carbocyclic Analogues of SGLT2 inhibitors
- Discovery of natural SGLT2–inhibitors for Type 2 Diabetes–Possible Way to Reduce Side Effects
- A Medical Literature Review on Canagli?? ozin and Dapagli?? ozin and the Role of SGLT2 inhibitors in Diabetic Management
- SGLT2 inhibitors–IS THE PARADIGM IN TYPE 2 DIABETES MELLITUS MANAGEMENT CHANGING?
- SGLT2 inhibitors and Ketoacidosis: Cause for Concern?
- Frequently asked questions: SGLT2 inhibitors–a novel approach to managing hyperglycaemia
- SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
- Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
- SGLT2–inhibitors in the Management of Type 2 Diabetes
- Glucose Lowering Effect of SGLT2 inhibitors: A Review of Clinical Studies
- www. OpenCME. org/course/where-do-SGLT2–inhibitors-fit-spectrum-of-treatment-of-t2dm
- Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 inhibitors in Type 2 DM Subjects
- “The Proof is in the Pudding”: Do SGLT2 inhibitors Cause Diabetic Ketoacidosis?
- APPLICATION OF THE MINIMAL MODEL IN SUBJECTS TREATED WITH SGLT2 inhibitors
- Relation Between HbA1c Level and Effectiveness of SGLT2 inhibitors in Diabetic Patients With Acute Decompensated Heart Failure
- Predictors of response to SGLT2–inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
- Efficacy of SGLT2 inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
- SGLT2 inhibitors: A Novel Therapy for Type 2 Diabetes Mellitus
- Survey of Patient Comprehension of Medication Instructions for SGLT2 inhibitors
- Meta-analysis of SGLT2 inhibitors and stroke risk in type 2 diabetic patients
- The Renoprotective Effects of SGLT2 inhibitors versus Placebo in Patients with Type 2 Diabetes with or
- SGLT2 inhibitors–new oral hypoglycemic drugs inhibitory SGLT2–nowe doustne leki przeciwcukrzycowe
- Effects of SGLT2 inhibitors in the treatment of a population with type 2 diabetes mellitus
- MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes
- The metabolic effects of SGLT2 inhibitors-Does the increase in ketone bodies protect the heart?
- Maximizing Patient Safety with Newly Approved Therapies: Focus on SGLT2 inhibitors
- FP408 NOVEL MOLECULAR MECHANISMS IN THE RENOPROTECTIVE EFFECT OF SGLT2 inhibitors VIA MITIGATION OF TUBULAR HYPOXIA AND PROTEIN …
- 163-LB: Impact of SGLT2 inhibitors on Liver Function Test in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-analysis
- 2347-PUB: Relationship between Aging and Effects of SGLT2 inhibitors on Glucose and Lipid Metabolisms and Hepatic Function in Japanese Patients with Type 2 …
- Letter to the Editor: Comment on “SGLT2 inhibitors may predispose to ketoacidosis” by Taylor SI, et al
- SGLT2 inhibitors as adjunct therapy to insulin in type 1 diabetes: Meta analysis
- 1962-P: Comparison of the Effects of Three SGLT2 inhibitors on Metabolic Parameters and Insulin Sensitivity in a Nondiabetic Rat Model of Metabolic Syndrome
- The Role of SGLT2 inhibitors and DPP4 inhibitors in Preventing Diabetic Nephropathy
- 1217-P: The Kidney Effects of the SGLT2 inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
- Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes
- 2350-PUB: Renoprotective Effects of SGLT2 inhibitors in Japanese Real-World Clinical Practice
- Effect of SGLT2 inhibitors on glucagon secretion in pancreatic alpha cells
- SUN-155 Clinical Experience of SGLT2 inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
- Euglycemic diabetic ketoacidosis in type 2-diabetes mellitus treated with SGLT2 inhibitors-a report on two cases
- An Overview On Aryl C-glycosides As SGLT2 inhibitors With Antidiabetic Potential.
- Evaluating Drug Cost per Response with SGLT2 inhibitors in Patients with Type 2 Diabetes Mellitus
- Efficacy and Usefulness of SGLT2 inhibitors in Niddm Patients on the Backdrop of Metformin and Sulphonyl Urea
- Improved preparation of C-aryl glucoside SGLT2 inhibitors
- Prevalence of psychiatric comorbidities in diabetic patients who are candidates for therapy with SGLT2 inhibitors: clinical and metabolic characteristics
- 25-LB: SGLT2 inhibitors Are Renoprotective via Mitigation of Tubular Hypoxia and Protein O-GlcNAcylation
- An audit of SGLT2–inhibitors in the management of type 2 diabetes in Sligo University Hospital Ireland: metabolic and haemodynamic outcomes
- ASSESSMENT OF SGLT2 inhibitors ON KIDNEY MORPHOLOGY AND ALBUMIN EXCRETION IN RATS WITH EXPERIMENTAL DIABETES MELLITUS TYPE 1.
- 2340-PUB: Success of Online CME at Improving the Clinical Knowledge and Confidence in Using SGLT1/SGLT2 inhibitors in T1D Management
- Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
- 2354-PUB: Estimating Improvement of TGF Mechanism from Changes of Urinary Glucose and Sodium Excretion by SGLT2 inhibitors
- Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors
- Impact of SGLT2 inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
- FP451 SIGNIFICANCE OF RENAL AUTONOMIC NERVES FOR WEIGHT-REDUCTION BY SGLT2 inhibitors
- Meet the SGLT2 inhibitors: these new type 2 diabetes medications block glucose reabsorption by the kidneys
- THE EMERGING ROLE OF SGLT2 inhibitors IN THE TREATMENT OF TYPE 2 DIABETES FOCUS ON EMPAGLIFLOZIN
- OR22-1 Liraglutide as Add-on to SGLT2 inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double …
- Cardiorenal protection with SGLT2 inhibitors (gliflozins): from EMPA-REG OUTCOME to CANVAS
- 2363-PUB: The efficacy of low vs. high FDA-approved SGLT2 inhibitor dose compared with DPP-4 inhibitors: a meta-analysis
- Effects Of GLP-1 Analogues, DPP-4 inhibitors And SGLT2 inhibitors On The Renal System
- Persistence to Treatment with DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1-RAs Compared with Insulin after Failure with First Antidiabetic Drug in T2DM Patients
- Comparative Cardiovascular Efficacy of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 Agonists—A Network Meta-analysis
- Comparative Effectiveness of SGLT2 inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes
- Disparities in the prescribing of DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 analogues in UK primary care
- Cover Feature: Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes (Chem. Eur. J. 12/2018)
- A survey of various adjuvant treatments used against type 1 diabetes, focusing on SGLT2 inhibitors
- 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
- SGLT2 inhibitors Increase Bone Strength by Increasing Procollagen Type 1 Amino-Terminal Propeptide in Patients with Type 2 Diabetes
- Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action
- Rates of myocardial infarction and stroke in patients initiated on SGLT2–inhibitors versus other glucose-lowering agents in real-world clinical practice: results …
- Control of Blood Glucose with Sodium Glucose Co-transporter 2 (SGLT2) inhibitors Among Patients with Type 2 Diabetes Mellitus
- … in type 2 diabetes: harnessing individual-level trial data alongside routine care records to identify predictors of response to SGLT2 inhibitors and DPP4 inhibitors
- Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors Drug Class Review
- The Positive Effect of the Combination of GLP-1 Analogues and SGLT2 inhibitors on Obese Patients with Noninsulin-Treated DM2
- … Glucose Co-Transporter 2 (SGLT2) inhibitors and Fracture Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Short running title: SGLT2 inhibitors …
- Type 2 Diabetes, SGLT2 inhibitors, and Glucose Secretion
- Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors: Comparing Trial and Real World Use (Study Protocol)
- The efficacy and safety of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- National prevalence of heart failure in type 2 diabetes patients derived from the National eHealth System and their access to treatment with SGLT2 inhibitors or GLP-1 …
- Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Class Update: Sodium-glucose Cotransporter 2 (SGLT2) inhibitors
- 2300-PUB: The Efficacy and Safety of Combinations of SGLT2 inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: A Systematic Review and …
- Health Expenditure Comparison of Diabetic Patients on Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Vs Dipeptidyl Peptidase-4 (DPP4) inhibitors
- Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or …
- [PP. 05.19] EFFECTS OF SGLT2 inhibitors ON BLOOD PRESSURE, BAPWV, CAROTID ARTERIAL IMT AND ELASTIC MODULUS IN TYPE 2 DIABETIC …
- Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Cardiovascular Disease: A Systematic
- SYSTEMATIC REVIEW OF SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) inhibitors IN THE TREATMENT FOR PATIENTS WITH DIABETES …
- COMPARATIVE EFFICACY OF 3 SGLT2 inhibitors AS THE FIFTH DRUG IN THE MANAGEMENT OF TYPE 2 DM IN ASIAN INDIANS NOT CONTROLLED WITH …
- Sodium Glucose Co transporter 2 (SGLT2) inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
- A Five Featured Pharmacophore Model for the Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) inhibitors
- … of autonomous aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin …
- SY 10-3 SGLT2 inhibitors AS POTENTIAL ANTIHYPERTENSIVE AND RENOPROTECTIVE AGENTS
- P2521 Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a …
- SY 10-2 THE ROLE OF SGLT2 inhibitors IN THE MANAGEMENT OF T2DM
- PS 11-73 BLOOD PRESSURE AND BODY WEIGHT LOWERING EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORT 2 (SGLT2) inhibitors.
- Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 inhibitors—Analysis from the CVD-REAL 2 Study
- The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes
- Systematic Review of SGLT2 Receptor inhibitors in dual or triple therapy in type 2 diabetes
- The position of new antidiabetics in clinical practice: SGLT2 vs DPP4 inhibitors
- SGLT2 versus DPP4 inhibitors for Type 2 Diabetes: A Meta-analysis
- Empagliflozin-the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type
- Audit on sodium glucose cotransporter-2 inhibitors (SGLT2) at Nottingham University Hospitals
- Non-severe hypoglycemia risk difference between sulfonylurea and sodium-glucose cotransporter-2 inhibitors (SGLT2-I) as an add-on to metformin in …
- Extraglycemic effects of SGLT2 inhibitors: a review of the evidence
- Effects of SGLT2 inhibitors on kidney and cardiovascular function
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- SGLT2–inhibitors; more than just glycosuria and diuresis
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- Optimising the benefits of SGLT2 inhibitors for type 1 diabetes
- Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
- SGLT2 inhibitors may offer benefit beyond diabetes
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- Renal effects of SGLT2 inhibitors: an update
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
- SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function
- SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
- Diabetic ketoacidosis with SGLT2 inhibitors
- Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
- Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
- SGLT2 inhibitors and kidney outcomes in patients with chronic kidney disease
- What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
- Recommendations on the proper use of SGLT2 inhibitors
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
- SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
- SGLT2 inhibitors: the star in the treatment of type 2 diabetes?
- Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update
- Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
- The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
- SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
- An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent
- SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review
- Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients
- Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review
- SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding …
- Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018
- Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
- The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis
- Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
- SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
- Minireview: are SGLT2 inhibitors heart savers in diabetes?
- SGLT2 inhibitors–a potential treatment for Alport syndrome
- SGLT2 inhibitors in people with and without T2DM
- Use of SGLT2 inhibitors during Ramadan: an expert panel statement
- Regression of left ventricular hypertrophy with SGLT2 inhibitors
- Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
- CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis
- Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors
- SGLT2 inhibitors in Diabetic Kidney Disease
- SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients
- SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational …
- SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
- SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis
- Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?
- SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: a review
- Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
- Are SGLT2 inhibitors safe and effective in advanced diabetic kidney disease?
- Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics
- SGLT2 inhibitors, sodium and off-target effects: An overview
- We can finally stop worrying about SGLT2 inhibitors and acute kidney injury
- Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly
- SGLT2 inhibitors: diabetic kidney disease and beyond
- Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new …
- The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
- Does metformin interfere with the cardiovascular benefits of SGLT2 inhibitors? Questions about its role as the cornerstone of diabetes treatment
- Diabetic Agents, From Metformin to SGLT2 inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar
- The Effects of SGLT2 inhibitors on Lipid Metabolism
- The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
- SGLT2 inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
- Combination therapy with SGLT2 inhibitors for diabetic kidney disease
- Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to …
- Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance
- Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial …
- Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 inhibitors
- Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors
- Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors
- Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- SGLT2 inhibitors in liver patients
- The Role of SGLT2 inhibitors in Vascular Aging
- Focused updates: SGLT2 inhibitors in patients with heart failure and/or chronic kidney disease
- Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review
- Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
- Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease
- SGLT2 inhibitors and the autonomic nervous system in diabetes: a promising challenge to better understand multiple target improvement
- SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in asian versus non-asian patients
- The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and …
- Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
- Pharmacokinetic/pharmacodynamic properties and clinical use of SGLT2 inhibitors in non-Asian and Asian patients with type 2 diabetes and chronic kidney disease
- Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
- Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
- Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE
- Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of …
- SGLT2 inhibitors, What the Emergency Physician Needs to Know: A Narrative Review
- SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent …
- Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
- The sweet spot: heart failure prevention with SGLT2 inhibitors
- SGLT2 inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
- Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
- SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
- Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis
- SGLT2 inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
- Use of SGLT2 inhibitors in Older Adults: Scientific Evidence and Practical Aspects
- SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy
- Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19
- SGLT2 inhibitors and renal complications in type 1 diabetes
- Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis
- Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
- Emergence of SGLT2 inhibitors as Powerful Antioxidants in Human Diseases
- Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
- Why Choose Between SGLT2 inhibitors and GLP1-RA When You Can Use Both? The Time to Act Is Now
- SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort …
- Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis
- Recommendations on the proper use of SGLT2 inhibitors
- Subtype‐dependent reporting of stroke with SGLT2 inhibitors: implications from a Japanese pharmacovigilance study
- SGLT2 inhibitors for type 2 diabetes mellitus in adults: an overview of forty‐six systematic reviews
- Effect of SGLT2–inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
- Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 …
- Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled …
- A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
- SGLT2 inhibitors and bladder cancer: Analysis of cases reported in the European pharmacovigilance database
- The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics
- SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial
- The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies
- Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database
- Impact of SGLT2 inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
- Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
- SCORED and SOLOIST: the next scores for SGLT2 inhibitors
- The Multiple Effects of SGLT2 inhibitors Suggest Potential Benefit in COVID-19 Patients
- Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized …
- SGLT2 inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
- Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
- SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a …
- Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension
- Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes
- Effects of SGLT2 inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization
- Unexpected Pleiotropic Effects of SGLT2 inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
- Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2–inhibitors: a review
- The Role of SGLT2 inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
- SGLT2 inhibitors, hemodynamics, and kidney protection
- Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study
- Are SGLT2 inhibitors New Hypertension Drugs?
- Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
- SGLT2 inhibitors across the Spectrum of Severity of CKD
- Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
- SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
- SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
- Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
- Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
- Syntheses of SGLT2 inhibitors by Ni-and Pd-Catalyzed Fukuyama Coupling Reactions
- Endogenous Fructose Metabolism Could Explain the Warburg Effect and the Protection of SGLT2 inhibitors in Chronic Kidney Disease
- Safety and Efficacy of SGLT2 inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
- Biocomputational Prediction Approach Targeting FimH by natural SGLT2 inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 inhibitor Drugs
- Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2–inhibitors and glp1-receptor agonists
- Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy
- SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
- SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
- SGLT2 inhibitors: expanding their Empire beyond diabetes
- Organ protection beyond glycaemic control with SGLT2 inhibitors
- SGLT2 inhibitors and the Mechanisms Involved in Weight Loss
- Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study
- Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
- SGLT2 inhibitors: the story continues to unfold
- SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
- Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland
- Effects of Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
- Are current SGLT2 inhibitors efficacious treatment options for Type 1 diabetes?
- Are the protective effects of SGLT2 inhibitors a” class-effect” or are there differences between agents?
- SGLT2 inhibitors in Resistant Hypertension: A Sweet Solution
- Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes of the adult
- Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
- SGLT2 inhibitors reduce all-cause mortality
- Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
- The influence of long‐term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney …
- SGLT2 inhibitors: renal outcomes according to baseline albuminuria
- SGLT2 inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics
- GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
- Cardioprotection by SGLT2 inhibitors—Does It All Come Down to Na+?
- Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
- The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation
- Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
- Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
- Effectiveness and Safety of SGLT2 inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
- Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 inhibitors in Patients Without T2DM
- When and for Whom Should We Use SGLT2 inhibitors in HFrEF?
- A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
- SGLT2 inhibitors in cardiovascular medicine
- Can CMR Elucidate the Cardiovascular Benefit of SGLT2 inhibitors?
- Diabetes, heart failure and beyond: elucidating the cardioprotective mechanisms of sodium glucose cotransporter 2 (SGLT2) inhibitors
- Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital
- Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials
- SGLT2 inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases
- Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
- … “SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis” Cardiac, renal protection with SGLT2 inhibitors is evident but …
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A …
- SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis
- GLP-1 Receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
- Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 inhibitors: a Nationwide Cohort Study in the USA
- Efficacy and cardiovascular safety of SGLT2 inhibitors.
- Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors
- SGLT2 inhibitors: Who Should Prescribe Them for Patients With Heart Failure?
- Effect of SGLT2 inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- SGLT2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study
- Letter to the Editor regarding the article “SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis”
- Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 inhibitors
- SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
- The Pleiotropic Effects of SGLT2 inhibitors: Remodeling the Treatment of Heart Failure
- Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2–inhibitors: two case reports
- Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
- Global Mechanisms Proposed for Cardioprotective Effects of SGLT2 inhibitors
- SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
- SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report
- SGLT2 inhibitors: a narrative review of efficacy and safety
- SGLT2 inhibitors and the risk of diabetic ketoacidosis: A systematic review and meta-analysis
- SGLT2 inhibitors and euglycemic diabetic ketoacidosis
- How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Completed and …
- Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
- Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
- Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
- Efficacy of Continuing SGLT2 inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure
- Can treatment response to SGLT2–inhibitors in syndrome of inappropriate antidiuresis be predicted by Copeptin, natriuretic peptides and inflammatory markers?
- Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
- SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis
- Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials
- Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
- Real-life prescribing of SGLT2 inhibitors: How to handle other medications, including glucose-lowering drugs and diuretics
- Meta-analysis of the effect of SGLT2 inhibitors on hepatic fibrosis in patients with T2DM complicated with NAFLD.
- Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors
- Marked hypertriglyceridemia in a patient with type 2 diabetes receiving SGLT2 inhibitors
- Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
- The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure
- SGLT2 inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials
- SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
- In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
- Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for Cardiovascular and Renal Points of View
- SGLT2 inhibitors Induced Hypercalcemia: A Case Series and Literature Review.
- The Rationale and Evidence for SGLT2 inhibitors as a Treatment for Nondiabetic Glomerular Disease
- Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An …
- Do SGLT2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?
- 324-OR: Global Use of SGLT2 inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
- Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta …
- The effect of SGLT2 inhibitors on silent myocardial ischemia
- Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.
- Cardiovascular Safety of SGLT2 inhibitors Compared to DPP4 inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World …
- Relationship Between HbA1c Level and Effectiveness of SGLT2 inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus
- MO647 RENOPROTECTIVE EFFECT OF SGLT2 inhibitors AFTER FIVE YEARS OF TREATMENT: AN OBSERVATIONAL STUDY
- The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
- Under-prescription of SGLT2 inhibitors in patients with diabetes and cardiovascular disease in the United States
- SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis
- Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus–New Findings on SGLT2 inhibitors
- EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR …
- Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors
- Does Combination Therapy With SGLT2 inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients …
- Euglycemic DKA Associated With SGLT2 inhibitors
- SGLT2 inhibitors: the Gift that Keeps on Giving
- … of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors
- Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) inhibitors for the development of novel antidiabetic agents
- Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 inhibitors
- SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
- Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and …
- In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
- Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection …
- Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A Prospective Pilot Optical Coherence Tomography Angiography Study
- The Effects of SGLT2 inhibitors on Lipid Metabolism. Metabolites 2021, 11, 87
- Biochemical Interaction Analysis of natural SGLT2 inhibitors with Alzheimer Targets: A Computational Approach.
- To Heart “Fail” or Not? The Expanding Role of SGLT2 inhibitors
- Synthesis of Benzyl C‐Analogues of Dapagliflozin as Potential SGLT2 inhibitors
- Risk of DKA with SGLT2 inhibitors
- SGLT2 inhibitors: the Gift that Keeps on Giving
- Patient and clinical characteristics of heart failure patients concomitantly prescribed SGLT2 inhibitors and sacubitril/valsartan, a database cohort study using the …
- Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A …
- Effects of SGLT2 inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarization
- Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and …
- Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic …
- Efficacy and Safety of SGLT2 inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
- Clinical and Economic Rationale for the Early use of SGLT2 inhibitors in Patients with Type 2 Diabetes
- SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice.
- … effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors
- Efficacy of DPP-4 inhibitors and SGLT2 inhibitors compared to sulphonylureas in adult patients with diabetes with low c-peptide levels with or without anti-GAD65 …
- Payment Coverage and Health Economics of SGLT2 inhibitors
- A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF-Letter regarding the article’Baseline Characteristics of Patients with Heart Failure with …
- Do SGLT2 inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review
- A paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors.
- The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
- SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
- P1010 EFFECTS OF SGLT2 inhibitors ON DIABETIC NEPHROPATHY: PODOCYTURIA ON FOCUS
- … causes an increase in endog-enous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 inhibitors on EGP in …
- Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus—is metabolic reprogramming the mechanism for these …
- Optimizing Utilization of SGLT2 inhibitors in an Outpatient LVAD Population
- Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors: A case report
- Euglycemic Diabetic Ketoacidosis Caused by SGLT2 inhibitors and a Ketogenic Diet: A Case Series and Review of Literature
- Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors
- SGLT2 inhibitors: A new era for our patients
- BS16 The role of parasympathetic nervous system in the infarct-limiting effect of SGLT2 inhibitors
- Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors & Kidney Transplantation: What Are We Waiting For?
- MO654 REAL LIFE EXPERIENCE AFTER 20 MONTHS USING SGLT2 inhibitors
- Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
- SGLT2 inhibitors: only beneficial?
- Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke …
- SGLT2 inhibitors and kidney outcomes in the real world
- Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Life-Threatening Complications
- Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
- Real-World Clinical Experience with SGLT2 inhibitors: Use of Special Screening Tool for Type 2 Diabetes Patients to Avoid Serious Adverse Events: A Single-Centre …
- Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
- How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and …
- Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases
- P1038 NEPHROPROTECTIVE EFFECT OF SGLT2 inhibitors DURING FIRST YEAR OF TREATMENT
- SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.
- 1097-P: Disposition Index Is a Predictor of Urinary Glucose Excretion in Subjects Treated with SGLT2 inhibitors
- Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors: A Case Report and Review of Literature
- SGLT2 inhibitors: A revolution in therapeutics of a Major Non-Communicable Disease
- THE ROLE OF SGLT2 inhibitors BEYOND GLUCOSE-LOWERING TO CARDIO-RENAL PROTECTION
- Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
- Therapeutic interventions of novel SGLT2 inhibitors against metabolic disorders: inserting the association into perspectives.
- Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure
- SGLT2 inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature
- P1047 URICOSURIA AND URINARY GLUCOSE EXCRETION ON DIABETIC KIDNEY DISEASE (DKD) PATIENTES TREATED WITH SGLT2 inhibitors
- SGLT2 inhibitors: focus on kidneys and nephroprotection
- Possible Mechanisms of Action of SGLT2 inhibitors in Heart Failure
- 1145-P: SGLT2 inhibitors Improve Day-to-Day Glucose Variability in Patients with Type 1 Diabetes
- 36-OR: Comparative effectiveness of SGLT2 inhibitors vs. GLP-1 agonists
- Role of SGLT2 inhibitors in Heart Failure
- Evolving physicians’ perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting
- SGLT2 inhibitors and the Risk of Major Adverse Cardiovascular Events: A Multi-database Study Using a Prevalent New-User Design
- When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease.
- 35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
- SGLT2 inhibitors in diabetic and non-diabetic nephropathies
- SGLT2 inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease
- Weight loss differences seen between glucagon-like-peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter-2 (SGLT2) inhibitors for treatment of type …
- Cardiovascular Outcome in Patients Treated With SGLT2 inhibitors for Heart Failure: A Meta-Analysis
- RE: Should we stick to SGLT2 inhibitors?
- Cardio-Renal Benefits of SGLT2 inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Clinical Evidence.
- Why Are SGLT2 inhibitors Nephroprotective? Mechanisms of Action And Possible Benefits A Review
- The position of SGLT2 inhibitors in current medicine.
- P1009 RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 inhibitors
- SGLT2 inhibitors, new option to prevent or treat heart failure
- Cost Analysis of SGLT2 inhibitors in patients with type 2 Diabetes in India
- A Review of the Role of Type 2 Diabetes and SGLT2 inhibitors in Heart Failure with Preserved Ejection Fraction.
- Improving Utilization of SGLT2 inhibitors in the Inpatient Setting
- … -P: Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 inhibitors …
- SGLT2 inhibitors and Heart Failure Outcomes
- Mechanistic evaluation of the effect of SGLT2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems …
- Effects of SGLT2 inhibitors on stroke in type 2 diabetes according to baseline kidney function
- A Comprehensive Review on various HPLC based Analytical techniques used for the Estimation of SGLT2 inhibitors type of Antidiabetic drugs in various …
- SGLT2 inhibitors, beyond glucose-lowering effect: impact on nephrology clinical practice
- CLINICAL PRACTICE PATTERNS AND ATTITUDES ABOUT PRESCRIBING SGLT2 inhibitors AT A SINGLE-CENTER ACADEMIC SAFETY-NET HOSPITAL
- 778-P: SGLT2 inhibitors, GLP-1 Receptor Agonists, and DPP-4 inhibitors and Risk of All-Cause Hospitalization
- SGLT2 inhibitors in patients with chronic kidney disease: from clinical trials to guidelines and new prospects for clinical practice
- SGLT2 inhibitors–No Longer Just for Those with Diabetes
- Differential Cardiovascular and Renal Benefits of SGLT2 inhibitors and GLP1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus
- AGE AND SEX-BASED DIFFERENCES IN CARDIOVASCULAR OUTCOMES OF SGLT2 inhibitors
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 inhibitors-SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?
- Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
- SGLT2 inhibitors and their association with balanoposthitis and Fournier’s gangrene.
- EXPANDING THE ROLE OF SGLT2 inhibitors ACROSS THE DIABETIC SPECTRUM
- SGLT2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials.
- Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms: A systematic review
- Comparative effectiveness and safety of SGLT2 inhibitors versus metformin in patients with type-2 diabetes: An observational study using data from routine care.
- 198 Primary care use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease–are we missing a trick?
- SGLT2 inhibitors DECREASE CARDIOVASCULAR MORTALITY OR HEART FAILURE HOSPITALIZATIONS IN HEART FAILURE SUBGROUPS: A SYSTEMATIC …
- 101 Heart failure, diabetes and use of SGLT2 inhibitors–a missed opportunity
- SGLT2 inhibitors and CKD in 2021
- Reply to Comment: Is there any place for SGLT2–inhibitors in post-liver transplantation patients?
- Why are SGLT2 inhibitors a good choice in the management of Type 2 Diabetes Mellitus?
- Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction-Analysis from the CVD-REAL 2 Study.
- SGLT2 inhibitors in Patients with Diabetes and Cardiovascular Disease
- Safety of SGLT2 inhibitors: A Pharmacovigilance Study From 2015 to 2020 Based on FDA Adverse Event Report System Database
- Overview of Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors for the Treatment of Non-diabetic Heart Failure Patients
- SGLT2 inhibitors and diabetic nephropathy: sweet nothings
- … Ali, Muhammad Umer Ahmed, Sundas, Muhammad Aslam Khan, Qalb Khan, Gul Muhammad Memon, Izhan Ali Khan. Role of SGLT2 inhibitors in Heart Failure
- Correction to: Optimising the Benefits of SGLT2 inhibitors for Type 1 Diabetes
- CARDIOLOGIST USE OF SGLT2 inhibitors AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A …
- Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV
- SAFETY AND EFFICACY OF SGLT2 inhibitors POST ORTHOTOPIC HEART TRANSPLANTATION
- Effect of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors on Left Ventricular Remodelling and Longitudinal Strain: A Prospective Observational Study
- SGLT2 inhibitors: Do we need other evidences?
- In HFrEF Don’t Throw the Baby out with the Bathwater! SGLT2 inhibitors: Numbers Needed to Treat or Harm
- 777-P: Efficacy of SGLT2 inhibitors and GLP1-Receptor Agonists in Asians with Type 2 Diabetes: A Systemic Review and Meta-analysis
- SGLT2 inhibitors, GLP-1 Receptor Agonists, or Bariatric Surgery and Risks of All-Cause Mortality, Cardiovascular Diseases, End-Stage Renal Diseases, and Severe …
- 681-P: Effect of 3-Month Therapy with SGLT2 inhibitors and GLP-1 Agonists on Ambulatory Blood Pressure in Patients with Type 2 Diabetes Mellitus
- Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Effectiveness and safety of SGLT2 inhibitors compared to dipeptidyl peptidase (DPP)-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based …
- 081 Assessment of SGLT2 inhibitors use in Heart Failure Patients at a Tertiary Hospital
- Lowering the Risk of Gout: Another Benefits from Use of SGLT2 inhibitors
- SGLT2 inhibitors improved time in range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective single-center pilot study
- Evidences on SGLT2 inhibitors and NOACs and their relevance to the Bhutanese health system
- A Comparison of the Effects of SGLT2 inhibitors in Heart Failure Patients with Diabetes Versus Non-diabetic Patients
- 88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real …
- Real-life clinical experience with GLP1 analogs and SGLT2 inhibitors in the treatment of diabetes type 2 and obesity
- 402-P: Liraglutide Might Have Synergistic Renal Protection Effect with SGLT2 inhibitors in Rapidly Progressive Diabetic Kidney Disease
- Cardiorenal outcomes and T2DM control in new users of SGLT2 inhibitors in combination therapy
- Comparing impact of SGLT2 inhibitors and GLP-1 agonists on lipid profile among the patients with diabetes mellitus Type 2. Results of a prospective 18-week …
- 779-P: Prescribing of SGLT2 inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists
- In a real-world population, SGLT2 inhibitors resulted in a significant but less than expected reduction in HbA1c, weight and systolic blood pressure at 12 months …
- 172 Untold Story of SGLT2 inhibitors
- Effects and Safety of SGLT2 inhibitors on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of …
- THE INFLUENCE OF THE INTRODUCTION OF 3 NEW CLASSES OF DIABETES TYPE 2 MEDICATION (DPP-4 inhibitors, SGLT2 inhibitors AND GLP-1 …
- 787-P: Individualized Estimated GFR Slope Analysis Is Needed to Preserve Renal Function by SGLT2 inhibitors in Patients with DKD
- SGLT2 inhibitors ARE NOT ASSOCIATED WITH RISKS FOR AMPUTATION-A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED …
- EFFECT OF SGLT2 inhibitors ON LIPID PARAMETERS: A META-ANALYSIS OF 30 RANDOMIZED CLINICAL TRIALS AND 10,246 PATIENTS
- SGLT2 inhibitors for gout: Do these antihyperglycaemic agents reduce uric acid levels?
- Use of sodium-glucose co-transporter-2-inhibitors (SGLT2-Is) and risk of lower limb amputation
- Incidence of Heart Failure Hospital Admissions Among Type 2 Diabetes Mellitus Patients and the Potential Impact of SGLT2 inhibitors in Japan: A Population-based …
- 1431-P: Risk of Venous Thromboembolism amongst Initiators of SGLT2 inhibitors Compared with Other Glucose-Lowering Agents
- 987-P: Comparative Cardiovascular (CV) Effectiveness of SGLT2 inhibitors (SGLT2i) and GLP-1 Receptor Agonists (GLP-1 RA) in Patients with Type 2 Diabetes …
- 1124-P: SGLT2 inhibitors as Adjuvant Therapy for Type 1 Diabetes: An Italian Center Experience
- Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors In Type 2 Diabetes Mellitus Patients
- REVIEW OF EFFICACY AND SHORT TERM SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) inhibitors USE IN DIABETIC RENAL TRANSPLANT …
- Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
- Potential Unrealized Mortality Benefit of GLP-1 Receptor Agonists and SGLT2 inhibitors: A Report from the Veterans Health Administration Clinical Assessment …
- 2218-PUB: Initiation of SGLT2 inhibitors in Hospitalized Patients with CVD
- PRETREATMENT WITH SGLT2 inhibitors AMELIORATES CONTRAST-INDUCED NEPHROPATHY
- 1162-P: Coverage, Formulary Restrictions, and Average Retail Prices of SGLT2 inhibitors and GLP-1 Receptor Agonists across Medicare Part D Plans in 2019
- 1200-P: Use of SGLT2 inhibitors in Hospitalized Patients in an Academic Center
- 34-OR: SGLT2 inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
- 137-LB: Early Performance Under SGLT2 inhibitors in High-Risk Patients: EARLY PUSH Study: A Prospective Double-Blind Comparative Study
- 812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 inhibitors
- … Background between Patients with and without Increased Glucagon Secretion while on SGLT2 inhibitors: A Comparison of Canagliflozin and Other SGLT2 inhibitors
- 1211-P: Real-World Use of SGLT2 inhibitors in a Large US Safety-Net Health System
- 5PSQ-123 SGLT2 inhibitors in type 2 diabetes patients with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
- 141-LB: The Reality of Diabetic Ketoacidosis in Patients with Type 2 Diabetes Using SGLT2 inhibitors Revealed by a Nationwide Claim-Based Database in Japan
- Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention …
- 1141-P: Effects of SGLT2 inhibitors on Nighttime Sympathetic Nerve Activity, Heart Rate, Blood Pressure Variability, and Glycemic Variability in Type 2 Diabetic …
- Role of DPP-4 and SGLT2 inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
- 1433-P: Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 …
- 1115-P: Comparative Rate of Amputations among Type 2 Diabetes Patients Starting Different SGLT2 inhibitors
- 676-P: Ideal Ketone Test Training among Type 1 Patients in Context of Risk Associated with SGLT2 inhibitors
- SGLT2 inhibitors in CKD: Innovation after 20 years
- … therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
- … των αναστολέων του συν-μεταφορέα νατρίου-γλυκόζης 2, Mechanisms of action and organ protection of sodium-glucose cotran-sporter inhibitors-2 (SGLT2)
- Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
- Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
- 5, 5-Difluoro-and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
- natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes
- … of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, α-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2)
- Investigation on the Anti-diabetic Effects of Selected natural Products/Chinese Herbs by Inhibiting the Activity of Sodium-glucose Cotransporter 2 (SGLT2)
- From natural Product to New Diabetes Therapy: Phlorizin and the Discovery of SGLT2 inhibitor Clinical Candidates
- SGLT2 inhibition—a novel strategy for diabetes treatment
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- SGLT2 inhibition and kidney protection
- SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome
- Nephroprotection by SGLT2 inhibition: back to the future?
- SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review
- SGLT2 inhibition in the diabetic kidney–an update
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- SGLT2 inhibition and COVID-19: The road not taken.
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
- Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?
- Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition
- SGLT2 inhibition and heart failure—current concepts
- SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
- SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition
- SGLT2 inhibition and glucagon secretion in humans
- Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
- SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
- Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism
- More CREDENCE for SGLT2 inhibition
- Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat
- SGLT2 inhibition: changing what fuels the heart
- Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
- Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF …
- Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells
- SGLT2 inhibition to address the unmet needs in diabetic nephropathy
- The limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition
- Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
- SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
- Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and …
- SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in …
- Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
- SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the …
- SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
- Glucagon levels during short-term SGLT2 inhibition are largely regulated by glucose changes in patients with type 2 diabetes
- SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
- The role of glucagon in the acute therapeutic effects of SGLT2 inhibition
- Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: Focus on Alzheimer’s Disease and ischemia-related brain injury
- Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases
- Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 …
- SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr−/− type 1 diabetic mice
- Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?
- Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native …
- Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
- A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition
- Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
- Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
- SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease,’diabetic nephropathy’, IgA nephropathy and podocytopathies with …
- Concise and stereodivergent synthesis of carbasugars reveals unexpected structure-activity relationship (SAR) of SGLT2 inhibition
- SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus
- SGLT2 inhibition and ketoacidosis–should we be concerned?
- SGLT2 Inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a …
- SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the National Kidney Foundation
- Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus
- A variation on the theme: SGLT2 inhibition and glucagon secretion in human islets
- Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition
- An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program …
- Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose …
- The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery
- Predictors of the response of HbA1c and body weight after SGLT2 inhibition
- Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
- SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot
- Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels
- Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus
- SGLT2 inhibition: a new era in renoprotective medicine?
- SGLT2 inhibition: A novel prospective strategy in treatment of diabetes mellitus
- Hepatic gluconeogenic response to single and long-term SGLT2 inhibition in lean/obese male hepatic G6pc-reporter mice
- Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
- Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic …
- … treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 …
- SGLT2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation
- SGLT2 inhibition with dapagliflozin: a novel approach for the management of type 2 diabetes
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- Ertugliflozin (steglatro): a new option for SGLT2 inhibition
- Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly
- SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes
- SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose …
- Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus
- SGLT2 inhibition for cardiovascular diseases, chronic kidney disease and NAFLD
- Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta …
- SGLT2 inhibition may precipitate euglycemic DKA after bariatric surgery
- SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
- SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond
- The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
- Pharmacodynamic model of sodium–glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology
- Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry
- Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
- The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
- Synthesis of novel N-glycoside derivatives via CuSCN-catalyzed reactions and their SGLT2 inhibition activities
- Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes Mellitus?
- Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
- Renal effects of antisense-mediated inhibition of SGLT2
- Model‐based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin
- Research digest: SGLT2 inhibition in kidney and liver disease
- Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with …
- A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition
- SGLT2 is not expressed in pancreatic α-and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans
- Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose‐induced oxidative stress in type 1 diabetic mice
- SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis
- SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: an in-silico proof-of-principle of proteomics-based drug repurposing
- Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation
- MO620 ANTIFIBROTIC EFFECTS OF SGLT2 INHIBITION IN THE KIDNEY AND PROXIMAL TUBULAR CELLS
- SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?
- Softening the Stiff Heart: SGLT2 Inhibition and Diastolic Function
- Paternal Obesity and SGLT2 Inhibition Alter Expression of Placental Regulatory Genes
- Adaptive Response as a Potential Key Link between SGLT2 Inhibition and Renoprotection
- SGLT1 does compensate for SGLT2 inhibition
- What makes SGLT2 inhibition so effective in lowering blood glucose in diabetes?(689.5)
- Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
- Commentary: Benefits of SGLT2 inhibition in heart failure: A bellwether for importance of other metabolic pathways
- SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a …
- … 2 (SGLT2) inhibition causes an increase in endog-enous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 …
- What Does SGLT2 Inhibition Add in Managing Hyponatremia Secondary to Syndrome of Inappropriate Antidiuresis (SIAD)?
- Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue
- Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
- Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys
- SGLT2-inhibition and Vascular Euphoria a Reconciliation of Vascular Health and Disease Homeostasis.
- Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney
- SO022 EVALUATION OF GLOMERULAR HEMODYNAMIC CHANGES BY SGLT2 INHIBITION IN TYPE 2 DIABETIC RATS USING IN VIVO IMAGING TECHNIQUES
- … with insulin shows important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress
- P0984 SGLT2 INHIBITION PREVENTS RENAL FIBROSIS IN CYCLOSPORINE NEPHROPATHY
- LB005 KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’IN EMPA-REG OUTCOME
- Metabolic and endocrine effects of SGLT2 inhibition
- 150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?
- 396-P: SGLT2 Inhibition Suppresses Glucagon Response to Hypoglycemia in Male but Not Female Rats with Streptozotocin-Induced Type 1 Diabetes
- Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus
- The effect of SGLT2 inhibition on urinary adenosine excretion in patients with type 1 diabetes
- Can SGLT2 Inhibition with Empagliflozin Attenuate Cardiorenal Oxidative Stress Due to Its Antioxidant Effects?
- Protective role of SGLT2 inhibition against the kidney disease
- 323-OR: SGLT2 Inhibition Promotes Myocardial Ketone Utilization in the Normal and Failing Heart
- SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
- SGLT2 Inhibition and Exercise for the Diabetic Right Ventricle
- Newer Therapies for Diabetic Nephropathy and Their Cardiovascular Effects: SGLT2 inhibition in a kidney with reduced nephron number: modeling and …
- How does SGLT2 inhibition improve heart failure?
- Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibition
- A Novel Potential of SGLT2 Inhibition: Antifibrotic Effect in Diabetes
- Effects of SGLT2 Inhibition on eGFR and Glomerular and Tubular Damage Markers in Japanese Patients With Type 2 Diabetes
- SGLT2 Inhibition by Canagliflozin Ameliorates Diet-induced Obesity by Promoting Intra-adipose Sympathetic innervation.
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition
- Acute SGLT2 Inhibition and the Pressure Natriuresis Response in Rats with Type 1 Diabetes
- SGLT2 Inhibition Is Predicted to Reduce LV End Diastolic Pressure: A Mathematical Modeling Analysis
- 1127-P: SGLT2 Inhibition (SGLT2i) Mediated Urinary Glucose Excretion (UGE) Associations with Metabolic and Renal Hemodynamic Parameters
- 1865-P: SGLT2 Inhibition Compared with Iso-energetic/Low-Carbohydrate Diet Reprograms Systemic Substrate Oxidation in Type 2 Diabetes
- 155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose …
- SGLT2 Inhibition With Dapagliflozin Improves Coronary Vascular Derangement in the Leptin-Deficient Ob/ob Mice
- 1851-P: Renal Denervation Attenuates Endogenous Glucose Production Increase with SGLT2 Inhibition in Patients with Renal Transplant Recipients and Impaired …
- SGLT2 Inhibition Ameliorates Exercise-Induced Pulmonary Hypertension (EIPH) in Heart Failure with Preserved Ejection Fraction
- 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
- SGLT2 Inhibition Is Predicted to Increase NaCl Delivery to the Medullary Thick Ascending Limb But Not to Significantly Elevate Its Oxygen Consumption
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in …
- 142-LB: Very Low Dose SGLT2 Inhibition Is as Effective as Angiotensin II Receptor Blockage for Cardiac and Renal Fibrosis in High Salt 5/6 Nephrectomized Rats
- Erratum to: SGLT1 does compensate for SGLT2 inhibition [Eur Heart J Cardiovasc Pharmacother (2016) 2 (4): 256] The reference to Figure 2, segments S1 and …
- Combining SGLT2 and DPP-4 Inhibition in Type 2 Diabetes
- … with insulin exerts important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress
- The Hatter Cardiovascular Institute scientific meeting on SGLT2 inhibition
- SGLT2 is not expressed in pancreatic alpha and beta cells and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans
- 492-P: A Novel Renoprotective Target of SGLT2 inhibitor: HIF-1α Inhibition and AMPK Activation in Renal Proximal Tubular Epithelial Cells
